loading

Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten

pulisher
May 29, 2025

40,289 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by BNP Paribas Financial Markets - Defense World

May 29, 2025
pulisher
May 28, 2025

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference - The Globe and Mail

May 28, 2025
pulisher
May 27, 2025

Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com

May 27, 2025
pulisher
May 27, 2025

As Gold Pushes Higher, Junior Miners Begin to Show Signs of Life - The Globe and Mail

May 27, 2025
pulisher
May 27, 2025

Palantir vs. IBM: The Breakthrough Wall Street Is Missing - The Globe and Mail

May 27, 2025
pulisher
May 27, 2025

Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail

May 27, 2025
pulisher
May 25, 2025

Northern Trust Corp Purchases 51,351 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

May 25, 2025
pulisher
May 22, 2025

3 Penny Stocks With Market Caps As Low As $70M To Watch - Yahoo Finance

May 22, 2025
pulisher
May 20, 2025

Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox - Genetic Engineering and Biotechnology News

May 20, 2025
pulisher
May 20, 2025

Promontory Therapeutics Announces Successful End of Phase 2 Meeting with US FDA on Phase 3 Registrational Study Design for PT-112 in Patients with Metastatic Castration-Resistant Prostate Cancer - PR Newswire

May 20, 2025
pulisher
May 16, 2025

Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Holdings Increased by Dimensional Fund Advisors LP - Defense World

May 16, 2025
pulisher
May 14, 2025

Leerink Partnrs Analysts Lower Earnings Estimates for DSGN - The AM Reporter

May 14, 2025
pulisher
May 13, 2025

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Quantum Sandbox Act: Why These 3 Quantum Stocks Could Be Ready to Explode - The Globe and Mail

May 13, 2025
pulisher
May 12, 2025

Q2 EPS Forecast for Design Therapeutics Reduced by Analyst - Defense World

May 12, 2025
pulisher
May 12, 2025

Chardan Capital Issues Optimistic Forecast for CRSP Earnings - Defense World

May 12, 2025
pulisher
May 12, 2025

FY2025 EPS Estimates for EYPT Decreased by Cantor Fitzgerald - Defense World

May 12, 2025
pulisher
May 12, 2025

Wells Fargo & Company MN Boosts Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

May 12, 2025
pulisher
May 12, 2025

FY2025 Earnings Forecast for GPCR Issued By Leerink Partnrs - Defense World

May 12, 2025
pulisher
May 09, 2025

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - The Globe and Mail

May 09, 2025
pulisher
May 08, 2025

Ataxia Pipeline: Advancing Therapeutics and 32+ Leading - openPR.com

May 08, 2025
pulisher
May 08, 2025

Barclays PLC Has $639,000 Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

May 08, 2025
pulisher
May 08, 2025

Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins (IDPs) and Advance Small-Molecule Therapeutics at Scale - Morningstar

May 08, 2025
pulisher
May 07, 2025

Design Therapeutics Inc Files For Mixed Shelf Of Up To $300 MillionSEC Filing - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

Design Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 07, 2025
pulisher
May 07, 2025

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results - The Manila Times

May 07, 2025
pulisher
May 07, 2025

Design Therapeutics, Inc. SEC 10-Q Report - TradingView

May 07, 2025
pulisher
May 07, 2025

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter ... - Bluefield Daily Telegraph

May 07, 2025
pulisher
May 06, 2025

Invesco Ltd. Buys New Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

May 06, 2025
pulisher
May 06, 2025

AI Proteins to Present Key Advances in Miniprotein Therapeutics Development at PEGS Boston 2025 - Business Wire

May 06, 2025
pulisher
May 05, 2025

Friedreich's Ataxia Market Growth | Trends, Treatments & - openPR.com

May 05, 2025
pulisher
May 02, 2025

Design Therapeutics reports positive outcomes from trial of DT-168 eye drops - Yahoo Finance

May 02, 2025
pulisher
May 02, 2025

Design Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView

May 02, 2025
pulisher
May 01, 2025

Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated' - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Design Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025 - Nasdaq

May 01, 2025
pulisher
May 01, 2025

Design Therapeutics (DSGN) Reveals Positive Phase 1 Trial Results for DT-168 | DSGN Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy - The Manila Times

May 01, 2025
pulisher
May 01, 2025

JPMorgan Chase & Co. Buys 48,528 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

May 01, 2025
pulisher
Apr 29, 2025

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PR Newswire

Apr 29, 2025
pulisher
Apr 27, 2025

Geode Capital Management LLC Purchases 3,090 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Apr 27, 2025
pulisher
Apr 24, 2025

Applying computational protein design to therapeutic antibody discoverycurrent state and perspectives - Frontiers

Apr 24, 2025
pulisher
Apr 23, 2025

Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs - Business Wire

Apr 23, 2025
pulisher
Apr 21, 2025

Biotech stocks jump as Makary outlines FDA vision, RBC comments - Baystreet.ca

Apr 21, 2025
pulisher
Apr 21, 2025

Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025 - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 - The Manila Times

Apr 21, 2025
pulisher
Apr 21, 2025

Design Therapeutics Phase 1 Data Shows Promise for Novel FECD Eye Drop Treatment | DSGN Stock News - Stock Titan

Apr 21, 2025
pulisher
Apr 21, 2025

Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics - Business Wire

Apr 21, 2025
pulisher
Apr 18, 2025

Forget the Correction: 2 Artificial Intelligence Stocks That Are Still Worth Buying Anyway - The Globe and Mail

Apr 18, 2025
pulisher
Apr 18, 2025

April 2025's Promising Penny Stocks - Yahoo Finance

Apr 18, 2025
pulisher
Apr 17, 2025

Design Therapeutics names new Chief Medical Officer By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

Design Therapeutics Names Chris Storgard as Chief Medical Officer - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics - Business Wire

Apr 17, 2025
pulisher
Apr 17, 2025

Design Therapeutics names new Chief Medical Officer - Investing.com Australia

Apr 17, 2025
$1.0846
price down icon 1.76%
$29.97
price down icon 0.70%
$577.79
price up icon 0.89%
$306.27
price up icon 0.67%
$4.47
price down icon 2.22%
$489.50
price down icon 0.11%
Kapitalisierung:     |  Volumen (24h):